GB2471565A — Use of tetrahydrocannabivarin (THCV) and/or cannabidiol (CBD) in the treatment of epilepsy
Assigned to GW Pharma Ltd · Expires 2011-01-05 · 15y expired
What this patent protects
Use of the phyto-cannabinoids tetrahydrocannabivarin (THCV) and/or cannabidiol (CBD) in the treatment of epilepsy and more particularly generalized (tonic and/or clonic) and/or partial seizures. The daily dose of THCV is preferably at least 1.5 mg and more preferably at least 15 …
USPTO Abstract
Use of the phyto-cannabinoids tetrahydrocannabivarin (THCV) and/or cannabidiol (CBD) in the treatment of epilepsy and more particularly generalized (tonic and/or clonic) and/or partial seizures. The daily dose of THCV is preferably at least 1.5 mg and more preferably at least 15 mg. The daily dose of CBD is preferably at least 400 mg and more preferably 400-800 mg. The embodiments relate to the use of pure CBD or to the use of THCV, as a pure compound or as a plant extract in which significant amounts of any THC naturally present has been selectively removed.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.